Over time, chronic back pain can impact not just mobility but also mental and physical well-being, often affecting sleep, mood, and overall quality of life. If left unmanaged, it can lead to a ...

DOI: 10.1126/sciadv.abc5219 In a new discovery, chronic pain has been shown to be physiologically different from acute pain and now scientists have the roadmap for how to target it.

Chronic mucocutaneous candidiasis (CMC) is a condition characterised by recurrent or persistent infections of the skin, nails and mucous membranes caused predominantly by Candida species. A ...

It found that chronic smoking of marijuana or ingesting it can harm our blood vessels. It's those organs in our body that help our heart function. "The less inflammation, the better.

Here are some the causes of chronic kidney disease. Chronic kidney disease increases the risk of cancer, know what causes CKD Image Source : AI-generated Written By: Debosmita Ghosh ...

Mucocutaneous candidiasis is behind this type of yeast infection. It affects the mucous membranes in the throat and esophagus. Esophageal yeast infections can occur if oral thrush is left untreated.

A new molecule developed by UB researchers acts like a local, long-lasting anesthetic, providing robust pain relief for up to three weeks, according to the results of preclinical studies reported ...

Chronic pain is defined as pain that persists beyond acute pain, typically over six months. It can be initiated with an injury or disease, but may persist after the triggering injury has healed.

Delhi plans elevated road over Ring Road to ease chronic congestion; Rs 6,000 crore project spans 55km, needs no land acquisition Atul Mathur / TNN / Updated: Jun 08, 2025, 11:25 IST ...

The statistics cited are sobering. Over 40 percent of American children now have at least one chronic disease, with childhood obesity increasing by more than 270 percent since the 1970s. As a ...

GSK’s antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, will get a rapid six-month review from the FDA when it is filed for approval, said the drugmaker this morning.

Novartis closes on filings for oral BTK drug remibrutinib as a treatment for chronic spontaneous urticaria after reporting 52-week data.